INTRODUCTION: To describe the population admitted in an emergency department of a teaching hospital for severe @entity548 associated with direct oral anticoagulants (DOAC). METHOD: During a three-year period (2012-2014) @entity1 older than 16years were prospectively identified by @entity548 symptoms from computerised requests. At least one of the following criteria defined major @entity548 : @entity548 , unstable haemodynamic, need for transfusion or haemostatic procedure, or a life threatening location. RESULTS: Fifty four @entity1 , 23 receiving @entity3926 , 30 @entity3925 and one @entity5424 were included, 2 in 2012, 35 in 2013 and 17 in 2014. Median age was 84years (range 63-99) with a sex ratio of 1.16. @entity548 complications were gastrointestinal (n=27), intracranial (n=12) or miscellaneous (n=15). Indication of DOAC was @entity64 prevention in @entity955 in 49 cases and @entity1150 in 5 cases. Hospitalization was required for 45 @entity1 (83%) with a mean length of stay of 8.5days. Sixteen @entity1 needed intensive care. Reversal therapy was prescribed in 11 @entity1 . At 1month, overall mortality was 24%, reaching 41.7% for @entity932 . Among surviving @entity1 , DOAC was stopped in 10 cases, continued in 17 @entity1 and switched for other antithrombotic in 17 @entity1 . CONCLUSION: Our study contributes to the post marketing surveillance of major @entity548 complications associated with DOAC. It takes part to the knowledge about the course of this severe event in emergencies. Careful awareness in risk benefit assessment, especially in elderly, is needed.

Emergency admissions for major XXXX associated with direct oral anticoagulants.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial haemorrhage'] @entity548 :: ('MESH:D006470', 'Disease') :: ['Haemorrhagic', 'haemorrhagic shock', 'bleeding', 'haemorrhage', 'haemorrhagic'] @entity3926 :: ('MESH:C554682', 'Chemical') :: ['dabigatran'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity5424 :: ('MESH:C522181', 'Chemical') :: ['apixaban'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']
@entity548 :: (MESH:D006470,Disease) :: ['haemorrhage']
